Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

Similar documents
Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Substance Use Disorders

ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH

Chapter 7. Screening and Assessment

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) دکتر راد گودرزی

*IN10 BIOPSYCHOSOCIAL ASSESSMENT*

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO

Dr. Renner receives honoraria from Reed Medical Education

Hot Topics in Addiction Medicine. Timothy Fong MD 44 th Annual Family Medicine Refresher March 2017

DRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS

BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy

UNDERSTANDING THE DISEASE OF ADDICTION by Suresh Joseph

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

Substance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %

SUBSTANCE USE DISORDER IN ADOLESCENT POPULATION

THE STATE OF MEDICINE IN ADDICTION RECOVERY

Substance Use Disorders: What Can We Do to Help Break the Cycle of Addiction

Treatment Approaches for Drug Addiction

Substance use and addictive disorders in Palliative care

Opioid dependence: Detoxification

Addiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017

Medication-Assisted Treatment. What Is It and Why Do We Use It?

ADS. 10. There have been times when I have been jealous or resentful of others.

Opioid Use Issues: All the Players

An Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM

MASS COMMUNICATIONS The traditional realm of mass communications includes television,

SCID-I Version 2.0 (for DSM-IV) Non-Alcohol Use Disorders

PHARMACOTHERAPY OF SMOKING CESSATION

DISCLOSURES MANAGEMENT OF OPIOID USE DISORDERS LECTURE COVERS. SUDs ARE IMPORTANT. I have nothing to declare

THE ADDICTED BRAIN: WHAT S GOING ON IN THERE? 3 CE hours. Sandra Morgenthal, PCC-S, CCFC, RN Copyright 2016 Sandra Morgenthal All rights Reserved

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

Alcoholism has been demonstrated to have a genetic component, especially among men.

Cases of Patients with OUD. Objectives

Clinical Evaluation: Assessment Goals

Welcome to the Opioid Overdose Prevention Project

ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment

Acute General Medical and Surgical Admission:

TOOL 1: QUESTIONS BY ASAM DIMENSIONS

MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS

Update on Medications for Tobacco Cessation

C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS

Opiate Use Disorder and Opiate Overdose

Objectives 11/2/2016. Managing Patients with Substance Abuse. Off Label Disclosure. Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

Addiction Medicine: What s new for primary care

Module II Opioids 101 Opiate Opioid

WHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS

Treatment Team Approaches in Substance Abuse Treatment

Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging.

Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions

Opioids. Sergio Hernandez, MD

Screening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders

Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs

Medical Interventions for Addiction in Primary Care Settings. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine

BASIC VOLUME. Elements of Drug Dependence Treatment

substance use and mental disorders: one, the other, or both?

Substance and Alcohol Related Disorders. Substance use Disorder Alcoholism Gambling Disorder

5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.

Treating Opioid Addiction

Ethics and. Diagnosis. John Lisy. Executive Director - Shaker Heights Youth Center Treasurer NAADAC LICDC-CS, OCPS II, LISW-S, & LPCC-S

SCENARIOS IN SUBSTANCE MISUSE. By Dr Gideon Felton Consultant Psychiatrist and Clinical Lead

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk

Pharmacologic Interventions for. Addictions

DSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW

Pharmacologic Therapy for Tobacco Use & Dependence

Medication Assisted Treatment

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

RECOMMENDATIONS FOR HEALTH CARE PROVIDERS

ALCOHOL/DRUG ASSESSMENT FORM

Medication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019

Smoking Cessation. Disclosures. Thank You. None

2/21/2018. What are Opioids?

Opioid Use in Youth. Amy Yule M.D. March 2,

Clinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date:

Psychosis, Mood, and Personality: A Clinical Perspective

Mental Health Nursing: Substance-Related Disorders. By Mary B. Knutson, RN, MS, FCP

Helping People Quit Tobacco

Triage, Assessment and Treatment Planning

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Breaking the Chains of Nicotine Dependence - A Breakthrough Approach

We admitted that we were powerless over alcohol that our lives had become unmanageable.

We admitted that we were powerless over alcohol that our lives had become unmanageable. Alcoholics Anonymous (AA) (2001, p. 59)

Effective Treatments for Tobacco Dependence

Serious Mental Illness and Opioid Use Disorder

How does cannabis affect my work performance?

Treating Addiction as a Chronic Illness: Why it is Finally Possible. A. Thomas McLellan Treatment Research Institute

Chantix Label Update 2018

Medications For Alcohol Use Disorder. DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow

3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine

Polysubstance Use & Medication-Assisted Treatment

Seek, Test, Treat and Retain for Criminal Justice Populations: Data Harmonization Measure

7/7/2016 Journal of the American Medical Association,

Prescription Opioid Addiction

Treatment of Alcohol and Opiate Withdrawal

Special Challenges Clinical Management of the HIV-Infected Drug User

Transcription:

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over use and continued use despite consequences. Previously, the DSM-IV differentiated between substance abuse and dependence Currently, the DSM-5 has combined these into substance use disorder severity and time course specifiers The term addiction is not a medically defined term and is not used in the DSM-5

In addition to the substance use disorder itself, patients may also experience substance-induced disorders Intoxication Withdrawal Substance/medication-induced mental disorder i.e. mood, anxiety, or psychotic symptoms, which onset during or shortly after the use of a substance, and may persist for up to one month after cessation of substance use. N.B. these may be a result of medications, not just street drugs (e.g. mania resulting from corticosteroids)

There are 10 classes of substance use disorders that are specified in DSM-5: 1. Alcohol 2. Caffeine 3. Cannabis 4. Hallucinogens 5. Inhalants 6. Opioids 7. Sedatives/Hypnotics/Anxiolytics 8. Stimulants (meth, cocaine, etc) 9. Tobacco 10. Other There are also some behavioural addictions such as gambling addiction, which appear to activate similar reward pathways as substance abuse.

Can generally be grouped into: Impaired control e.g. using more than intended, failure to cut down, spending excess time or money using, cravings Social impairment e.g. using despite social dysfunction or consequences Risky use e.g. using despite risks to physical or mental health Pharmacological criteria e.g. tolerance and withdrawal

1. Often used in larger amounts or over longer time than intended 2. Desire to cut down or unsuccessful attempts to cut down use 3. Much time is spent in obtaining, using, or recovering from use 4. Cravings 5. Use resulting in failure to fulfill major role obligations (home/work/school) 6. Continued use despite recurrent interpersonal problems related to use 7. Important activities reduced or given up due to use 8. Recurrent use despite physical hazard (e.g. driving while intoxicated, sharing gear, etc) 9. Recurrent use despite knowledge of negative physical or psychological consequences 10. Tolerance symptoms 11. Withdrawal symptoms

You cannot treat what you don t know about - ask everyone about smoking, alcohol, and drugs (both street and Rx) Screen with CAGE questionnaire for alcohol Severity specifier Mild: 2-3 symptoms Moderate: 4-5 symptoms Severe: 6+ symptoms

Establish Goals: Abstinence has best outcomes; other goals may be harm reduction or improved functioning Motivate the patient to change (eg MI or A- FRAMES techniques) Privacy applies in substance use disorders just as in all medical conditions. Exceptions include: -in the ER -duty to warn specific individuals who may be at risk of harm -suspected child abuse or neglect -driving safety concerns

SUBSTANCE Autonomics Pupils LOC Dangerous? Treatment Alcohol Withdrawal hyperactive N/A Agitated, anxious YES seizures, DTs Benzos (CIWA protocol) Opioid Intoxication hypoactive miosis Drowsy, coma YES respiratory depression Narcan (naloxone) Opioid withdrawal Hyperactive, diarrhea, rhinorrhea, nausea, aches mydriasis Normal NO Supportive measures Stimulant Intoxication Hyperactive, mydriasis Agitated, psychosis YES seizures, CVA,cardiac arrhythmia Supportive measures, symptomatic treatment

Psychosocial treatments: CBT, MI, 12-step therapy, marital/family therapy, group therapy, dynamic or IPT, self-help or 12-step groups (AA) Pharmacological treatment Naltrexone (50mg/day PO or q4weekly depot) decreases the pleasure associated with alcohol use, works best when combined with counseling. NOT for patients on opiates! Disulfiram (125-500mg/day) causes aversive reaction to any alcohol consumed, works best in reliable and motivated patients. Acamprosate (666mg TID) decreases cravings in abstinent patients, works best with recently abstinent and highly motivated patients.

Psychosocial treatment: CBT, behavioural, dynamic, group/family therapy, self-help and 12 step groups (NA) Pharmacological treatment NO EVIDENCE for ultra-rapid detox with naltrexone, this causes severe withdrawal, can have dangerous side effects to anaesthesia and is not effective in long term For patients with >1 year of dependence, can treat with an agonist to reduce the morbidity and mortality of opioid use, without necessarily having a goal of discontinuing opioids methadone 40-60mg/day to prevent withdrawal, larger doses (>80mg) to prevent cravings are associated with better success Full agonist at opioid receptor. Has risk of overdose, abuse or diversion; only at special dispensaries; metabolized through CYP 450 so watch for interactions buprenorphine 8-32mg daily, can be dosed q2-3 days, partial agonist at opioid receptor, available in combination with naloxone to reduce risk of abuse

Remember the effect of smoking on drugs metabolized through CYP450 Psychosocial Treatments abrupt cessation better than gradual taper helpful interventions include brief interventions, behavioural therapy, CBT, social supports (e.g. spouse) no evidence for inpatient treatment, hypnosis, 12-step Pharmacological Treatment First-line: Nicotine Replacement Therapy (patch, gum, lozenge, spray, inhaler) Bupropion XR (150mg/day x4 days, then 300mg/day, quit on day 7) Second-line: Nortriptyline (25mg/day, increase to 75mg/day, quit on day 10-14) Clonidine (0.1-0.4mg/day PO or patch) Varenicline (partial nicotine agonist) 0.5mg/day, titrate as tolerated to target of 1mg BID, quit on day 7, 12 week course, should not be taken with NRT (watch for psychiatric side effects)

Question 1 Withdrawal from which of these substances can be medically dangerous? (bonus points: what is the dangerous symptom we are worried about?) A. Heroin B. Alcohol C. Crack D. Gas huffing

Question 2 Mr. Jones is a 21 yo college student who drinks alcohol to the point of black out around 2 weekends per month. He had to go to the ER to get his stomach pumped last year, and has gotten in several fights while intoxicated, causing a girlfriend to dump him and his previous roommates to ask him to move out. He will usually start the night telling his friends that he wants to cut down on his drinking and will only have a couple beers but by the end of the night he has usually had 10 or more drinks. When he started drinking alcohol at age 15, 1-2 drinks would make him tipsy now he finds that he requires 4-6 drinks to get buzzed. He used to play Ultimate Frisbee on Saturdays but now finds he is usually too hungover and has quit the league in order to spend his Saturdays recovering from Friday night. He has driven on several occasions after drinking, but has never had an accident. He also smokes marijuana a few times a year, usually when someone offers him a joint at a party. He has had no cravings or withdrawal symptoms for either marijuana or alcohol. His bloodwork and physical exam are normal. What is his diagnosis? A. Alcohol use disorder, severe, PLUS cannabis use disorder, mild B. Alcohol use disorder, moderate, PLUS cannabis use disorder, mild C. Alcohol use disorder, moderate D. Alcohol use disorder, severe E. This is normal, I think this guy was in my class last year

Question 3 You are seeing a patient in the ER, and your attending asks you Do you think this could be opioid intoxication? You correctly answer: A. Yes, the patient is agitated and hallucinating, this could be opioid intoxication B. Yes, the patient is drowsy and tachycardic, with some soft neurological signs, this could be opioid intoxication C. Yes, the patient is drowsy with bradycardia and miosis, this could be opioid intoxication D. Yes, this patient is drowsy with bradycardia and mydriasis, this could be opioid intoxication

Question 4 Match the following treatments for alcohol use disorder with their intended effect: 1.Disulfiram 2.Naltrexone 3.Acamprosate A. causes aversive reaction to any alcohol consumed B. decreases cravings in abstinent patients C. decreases stimulation of the reward pathway associated with alcohol use

Question 5 Which of the following is NOT a type of psychotherapy used specifically in substance use treatment? A. CBT B. MI C. DBT D. 12-step programs

Question 6 The CAGE questionnaire is a useful screening tool for problematic alcohol use. What does it stand for? A. Ever been criticized, ever had an accident, ever felt guilty, ever needed an eye-opener? B. Ever felt need to cut down, ever been annoyed, ever felt guilty, ever needed an eye-opener? C. Ever had cravings, ever been annoyed, ever felt guilty, ever needed an eye-opener? D. Ever had cravings, ever had an accident, ever felt guilty, ever needed an eye-opener?

1. B (bonus: seizures) 2. D 3. C 4. 1 A, 2 C, 3 B 5. C 6. B

CIWA protocol as used at CAMH http://www.reseaufranco.com/en/assessment_and_treatment_information/assessment_tools/clinical_i nstitute_withdrawal_assessment_for_alcohol_ciwa.pdf APA Guidelines of Treatment of Patients with Substance Use Disorder http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf Mouse Party a simplified look at the effects of substances of abuse on the brain http://learn.genetics.utah.edu/content/addiction/mouse/